Pengfei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pengfei Zhang has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
Huanxing Han
Department of Pharmacy, Changzheng Hospital
9 shared publicationsWannian Yan
Shanghai Skin Disease Hospital, School of Medicine
6 shared publicationsYucheng Wang
Shanghai Sepfocus Technology Co. Ltd
4 shared publicationsLingzhi Fan
Department of Central Laboratory, Shanghai Skin Disease Hospital, School of Medicine, Tongji University
3 shared publications- Ru-Jia Yu
Nanjing University
3 shared publications Shouhong Gao
Department of Pharmacy
3 shared publications
Latest Publications
- 27 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (18) , 13546-13555
Digital Counting of Quantum Dots Nanobeads on Lateral Flow Test Strips Enables Ultrasensitive Point-of-Care Diagnostics
Lateral flow assay (LFA) is a versatile platform for the rapid detection of various pathogens, pollutants, and toxins at point of care (POC). However, a traditional lateral flow assay strip is still not sensitive enough for early detection of disease, and previous works to enhance the sensitivity of LFA systems have suffered from additional signal amplification chemistry, tedious operation procedure, or expensive signal amplification instruments. In this study, we introduced a digital counting strategy for signal measurement to improve the detection sensitivity of quantum dot nanobead-based lateral flow immunoassays, offering an alternative to traditional fluorescence intensity-based quantification. The ultrasensitive single-molecule POC detection system is composed of an ultrabright fluorescent quantum dot nanobead-based lateral flow assay strip and a portable fluorescent microscopy reader for numerating single immunocomplexes on a test line. As a proof-of-concept, we performed digital LFA to detect interleukin-6 in 1% BSA with LoD as low as 0.02 pg/mL, which is ∼100 times more sensitive than analog LFA. Moreover, an amplification-free assay for HIV RNA was also demonstrated by combining CRISPR-Cas13 reaction and digital LFA with a sensitivity of as low as 89 copies/mL. A prototype portable and affordable fluorescent microscopy reader was designed and demonstrated its ability to be used for on-site testing. All in all, the developed digital LFA system not only has single-molecule level sensitivity but also satisfies the rapidity, easy operation, portability, and low-cost requirements for POC testing.
- 27 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (18) , 13546-13555
Digital Counting of Quantum Dots Nanobeads on Lateral Flow Test Strips Enables Ultrasensitive Point-of-Care Diagnostics
Lateral flow assay (LFA) is a versatile platform for the rapid detection of various pathogens, pollutants, and toxins at point of care (POC). However, a traditional lateral flow assay strip is still not sensitive enough for early detection of disease, and previous works to enhance the sensitivity of LFA systems have suffered from additional signal amplification chemistry, tedious operation procedure, or expensive signal amplification instruments. In this study, we introduced a digital counting strategy for signal measurement to improve the detection sensitivity of quantum dot nanobead-based lateral flow immunoassays, offering an alternative to traditional fluorescence intensity-based quantification. The ultrasensitive single-molecule POC detection system is composed of an ultrabright fluorescent quantum dot nanobead-based lateral flow assay strip and a portable fluorescent microscopy reader for numerating single immunocomplexes on a test line. As a proof-of-concept, we performed digital LFA to detect interleukin-6 in 1% BSA with LoD as low as 0.02 pg/mL, which is ∼100 times more sensitive than analog LFA. Moreover, an amplification-free assay for HIV RNA was also demonstrated by combining CRISPR-Cas13 reaction and digital LFA with a sensitivity of as low as 89 copies/mL. A prototype portable and affordable fluorescent microscopy reader was designed and demonstrated its ability to be used for on-site testing. All in all, the developed digital LFA system not only has single-molecule level sensitivity but also satisfies the rapidity, easy operation, portability, and low-cost requirements for POC testing.
- 30 March 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (14) , 6235-6244
One-Step Coassembly of Quantum Dots and Amphiphilic Polymer into Superparticles for Highly Sensitive Lateral Flow Immunoassay
- 30 March 2026
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 9 (14) , 6235-6244
One-Step Coassembly of Quantum Dots and Amphiphilic Polymer into Superparticles for Highly Sensitive Lateral Flow Immunoassay
- 30 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (27) , 14612-14619
On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay
Therapeutic drug monitoring of program death-1 (PD-1) inhibitor Serplulimab in cancer patients is of clinical importance in predicting treatment efficacy and assessing adverse reactions. However, the traditional liquid chromatography tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) for antibody drug monitoring are time-consuming and laborious. Herein, a quantum dot nanobeads-based lateral flow immunoassay (LFIA) is developed for rapid and accurate monitoring of the PD-1 antibody drug in 15 min. Both competitive and indirect immunoassays were investigated for PD-1 antibody drug monitoring, and the competitive assay demonstrated better sensitivity and precision. The optimized competitive LFIA had a detection of limit of 5.1 μg/mL; a linear range of 10-100 μg/mL; recovery rates of 99.2%-113.9% at the spiked concentration of 25, 50 and 100 μg/mL; and coefficients of variations (CVs, n = 10) less than 14.5% at 50 μg/mL. The assay has a negligible nonspecific reaction with the interferents of other monoclonal antibody drugs, autoantibodies, hyper lipids, hemolysis, jaundice, and whole blood samples. Method comparison with ELISA in 30 human plasma samples has a good correlation factor of r = 0.87. All in all, the developed quantum dot nanobead-based LFIA system for PD-1 antibody drug monitoring is a versatile tool for rapidly personalized drug therapy at the point of care.
- 30 June 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (27) , 14612-14619
On-Site Therapeutic Drug Monitoring for Program Death-1 Antibody Using a Quantum Dot Nanobeads-Based Lateral Flow Immunoassay
Therapeutic drug monitoring of program death-1 (PD-1) inhibitor Serplulimab in cancer patients is of clinical importance in predicting treatment efficacy and assessing adverse reactions. However, the traditional liquid chromatography tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) for antibody drug monitoring are time-consuming and laborious. Herein, a quantum dot nanobeads-based lateral flow immunoassay (LFIA) is developed for rapid and accurate monitoring of the PD-1 antibody drug in 15 min. Both competitive and indirect immunoassays were investigated for PD-1 antibody drug monitoring, and the competitive assay demonstrated better sensitivity and precision. The optimized competitive LFIA had a detection of limit of 5.1 μg/mL; a linear range of 10-100 μg/mL; recovery rates of 99.2%-113.9% at the spiked concentration of 25, 50 and 100 μg/mL; and coefficients of variations (CVs, n = 10) less than 14.5% at 50 μg/mL. The assay has a negligible nonspecific reaction with the interferents of other monoclonal antibody drugs, autoantibodies, hyper lipids, hemolysis, jaundice, and whole blood samples. Method comparison with ELISA in 30 human plasma samples has a good correlation factor of r = 0.87. All in all, the developed quantum dot nanobead-based LFIA system for PD-1 antibody drug monitoring is a versatile tool for rapidly personalized drug therapy at the point of care.
- 19 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (8) , 4120-4128
Plasmon-Enhanced Quantum Dot Nanobead-Based Lateral Flow Assay with Lower Background and Improved Sensitivity
- 19 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 8 (8) , 4120-4128
Plasmon-Enhanced Quantum Dot Nanobead-Based Lateral Flow Assay with Lower Background and Improved Sensitivity
- 5 November 2024
- Published by Elsevier in Microchemical Journal
- Vol. 207
CRISPR-Cas12a based HSV DNA detection method using quantum dot-labeled immunochromatographic strips
- 5 November 2024
- Published by Elsevier in Microchemical Journal
- Vol. 207
CRISPR-Cas12a based HSV DNA detection method using quantum dot-labeled immunochromatographic strips
- 1 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (11) , 7659-7665
Dual-Fluorescent Quantum Dot Nanobead-Based Lateral Flow Immunoassay for Simultaneous Detection of C-Reactive Protein and Procalcitonin
Simultaneous detection of C-reactive protein (CRP) and procalcitonin (PCT) at the point of care is crucial for the management of infections in patients with inflammation and in critical care settings. The challenge of detecting high concentrations of CRP alongside low concentrations of PCT in plasma from inflammatory patients has limited the clinical application of multiplexed immunoassays. Herein, we developed a lateral flow immunoassay (LFIA) that employs quantum dot nanobeads (QDNBs) of varying sizes and colors to enable the simultaneous quantification of PCT and CRP in human plasma. To extend the dynamic range of CRP detection, we combined QDNBs with smaller particle sizes with the CRP detection antibodies, thereby increasing the assay's dynamic range and reducing the hook effect. At the same time, the stronger fluorescence emitted by these larger QDNBs, in conjugation with the PCT detection antibodies, allows for the detection of PCT at the nanogram level, meeting the demand for high sensitivity. The results show that this method can detect CRP concentrations from 0.1 to 3 mg/L and PCT with a detection limit of 0.09 ng/mL, which is on par with clinically used methods. By employing this dual-color and dual-size QDNB labeling strategy, we successfully achieved simultaneous detection of CRP with a broad dynamic range and PCT with high sensitivity in a one-step point-of-care rapid test.
- 1 November 2024
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 7 (11) , 7659-7665
Dual-Fluorescent Quantum Dot Nanobead-Based Lateral Flow Immunoassay for Simultaneous Detection of C-Reactive Protein and Procalcitonin
Simultaneous detection of C-reactive protein (CRP) and procalcitonin (PCT) at the point of care is crucial for the management of infections in patients with inflammation and in critical care settings. The challenge of detecting high concentrations of CRP alongside low concentrations of PCT in plasma from inflammatory patients has limited the clinical application of multiplexed immunoassays. Herein, we developed a lateral flow immunoassay (LFIA) that employs quantum dot nanobeads (QDNBs) of varying sizes and colors to enable the simultaneous quantification of PCT and CRP in human plasma. To extend the dynamic range of CRP detection, we combined QDNBs with smaller particle sizes with the CRP detection antibodies, thereby increasing the assay's dynamic range and reducing the hook effect. At the same time, the stronger fluorescence emitted by these larger QDNBs, in conjugation with the PCT detection antibodies, allows for the detection of PCT at the nanogram level, meeting the demand for high sensitivity. The results show that this method can detect CRP concentrations from 0.1 to 3 mg/L and PCT with a detection limit of 0.09 ng/mL, which is on par with clinically used methods. By employing this dual-color and dual-size QDNB labeling strategy, we successfully achieved simultaneous detection of CRP with a broad dynamic range and PCT with high sensitivity in a one-step point-of-care rapid test.
- 28 June 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 208
Fluorescent Lateral Flow Immunoassay Based on Quantum Dots Nanobeads
Quantum dots, also known as semiconductor nanocrystals, are novel fluorescent labels for biological imaging and sensing. However, quantum dot-antibody ... Jove
- 28 June 2024
- Published by MyJove Corporation in Journal of Visualized Experiments
- No. 208
Fluorescent Lateral Flow Immunoassay Based on Quantum Dots Nanobeads
Quantum dots, also known as semiconductor nanocrystals, are novel fluorescent labels for biological imaging and sensing. However, quantum dot-antibody ... Jove
- Open Access
- 8 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Plasmon-Enhanced Quantum Dot Nanobeads-Based Lateral Flow Assay with Lower Background and Improved Sensitivity
Developing a quantum dot (QD) nanobeads-based lateral-flow assay (LFA) is of great importance for achieving ultrasen-sitive, quantitative, and rapid testing of clinical specimens at the point-of-care. However, the QD nanobeads currently used in LFA still have drawbacks such as large particle size, which leads to high background, easy aggregation, and poor fluidity. To address these issues, a promising strategy is to utilize plasmonic energy transfer from gold nanoparticles (AuNPs) to QDs in order to create smaller size and brighter fluorescent QD nanobeads, without simply increasing the amount of QDs encapsulated in the nanobeads. In this study, we prepared the plasmon-enhanced quantum dot nano-beads (PEQNB) by encapsulating AuNPs and QDs into polymer nanobeads using the versatile emulsion-solvent evapora-tion method. We were able to detect as low as ~4347 PEQNBs nanoparticles using a gel imager, which is 14.6 times brighter than the QD nanobeads of a similar size. Compared to QD nanobeads of similar size, the PEQNB-based LFA for interleukin-6 detection exhibited higher fluorescent signal and lower background. The detection limit of PEQNB-based LFA was 1.63-fold higher than that of QD nanobeads. Furthermore, compared to larger-sized QD nanobeads with aver-age diameter of 131.1nm, PEQNB with average diameter of 78.6 nm based LFA exhibited similar levels of fluorescence intensity, but 1.55-fold lower background signal and 1.44-fold lower detection limits. This work demonstrates that opti-mized plasmon-enhanced QD nanobeads can further increase the sensitivity and lower the background signals of ultra-sensitive QD nanobeads-based LFA for disease diagnosis at point-of-care.
- 8 January 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessPlasmon-Enhanced Quantum Dot Nanobeads-Based Lateral Flow Assay with Lower Background and Improved Sensitivity
Developing a quantum dot (QD) nanobeads-based lateral-flow assay (LFA) is of great importance for achieving ultrasen-sitive, quantitative, and rapid testing of clinical specimens at the point-of-care. However, the QD nanobeads currently used in LFA still have drawbacks such as large particle size, which leads to high background, easy aggregation, and poor fluidity. To address these issues, a promising strategy is to utilize plasmonic energy transfer from gold nanoparticles (AuNPs) to QDs in order to create smaller size and brighter fluorescent QD nanobeads, without simply increasing the amount of QDs encapsulated in the nanobeads. In this study, we prepared the plasmon-enhanced quantum dot nano-beads (PEQNB) by encapsulating AuNPs and QDs into polymer nanobeads using the versatile emulsion-solvent evapora-tion method. We were able to detect as low as ~4347 PEQNBs nanoparticles using a gel imager, which is 14.6 times brighter than the QD nanobeads of a similar size. Compared to QD nanobeads of similar size, the PEQNB-based LFA for interleukin-6 detection exhibited higher fluorescent signal and lower background. The detection limit of PEQNB-based LFA was 1.63-fold higher than that of QD nanobeads. Furthermore, compared to larger-sized QD nanobeads with aver-age diameter of 131.1nm, PEQNB with average diameter of 78.6 nm based LFA exhibited similar levels of fluorescence intensity, but 1.55-fold lower background signal and 1.44-fold lower detection limits. This work demonstrates that opti-mized plasmon-enhanced QD nanobeads can further increase the sensitivity and lower the background signals of ultra-sensitive QD nanobeads-based LFA for disease diagnosis at point-of-care.
- 22 December 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (1) , 401-408
One-Component Dual-Readout Aggregation-Induced Emission Nanobeads for Qualitative and Quantitative Detection of C-Reactive Protein at the Point of Care
Fluorescent lateral flow immunoassay (LFA) systems are versatile tools for sensitive and quantitative detection of disease markers at the point of care. However, traditional fluorescent nanoparticle-based lateral flow immunoassays are not visible under room light, necessitate an additional fluorescent reader, and lack flexibility for different application scenarios. Herein, we report a dual-readout LFA system for the rapid and sensitive detection of C-reactive protein (CRP) in clinical samples. The system relied on the aggregation-induced emission nanobeads (AIENBs) encapsulated with red AIE luminogen, which possesses both highly fluorescent and colorimetric properties. The AIENB-based LFA in the naked-eye mode was able to qualitatively detect CRP levels as low as 8.0 mg/L, while in the fluorescent mode, it was able to quantitatively measure high-sensitivity CRP (hs-CRP) with a limit of detection of 0.16 mg/L. The AIENB-based LFA system also showed a good correlation with the clinically used immunoturbidimetric method for CRP and hs-CRP detection in human plasma. This dual-modal AIENB-based LFA system offers the convenience of colorimetric testing and highly sensitive and quantitative detection of disease biomarkers and medical diagnostics in various scenarios.
- 22 December 2023
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (1) , 401-408
One-Component Dual-Readout Aggregation-Induced Emission Nanobeads for Qualitative and Quantitative Detection of C-Reactive Protein at the Point of Care
Fluorescent lateral flow immunoassay (LFA) systems are versatile tools for sensitive and quantitative detection of disease markers at the point of care. However, traditional fluorescent nanoparticle-based lateral flow immunoassays are not visible under room light, necessitate an additional fluorescent reader, and lack flexibility for different application scenarios. Herein, we report a dual-readout LFA system for the rapid and sensitive detection of C-reactive protein (CRP) in clinical samples. The system relied on the aggregation-induced emission nanobeads (AIENBs) encapsulated with red AIE luminogen, which possesses both highly fluorescent and colorimetric properties. The AIENB-based LFA in the naked-eye mode was able to qualitatively detect CRP levels as low as 8.0 mg/L, while in the fluorescent mode, it was able to quantitatively measure high-sensitivity CRP (hs-CRP) with a limit of detection of 0.16 mg/L. The AIENB-based LFA system also showed a good correlation with the clinically used immunoturbidimetric method for CRP and hs-CRP detection in human plasma. This dual-modal AIENB-based LFA system offers the convenience of colorimetric testing and highly sensitive and quantitative detection of disease biomarkers and medical diagnostics in various scenarios.